Literature DB >> 19928731

Polarization-sensitive optical coherence tomography of necrotizing scleritis.

Masahiro Miura1, Masahiro Yamanari, Takuya Iwasaki, Masahide Itoh, Toyohiko Yatagai, Yoshiaki Yasuno.   

Abstract

A polarization-sensitive swept-source optical coherence tomography system (central wavelength: 1,310 nm; A-line rate: 20 kHz) was developed to evaluate the three-dimensional structure of the anterior eye segment with the phase retardation associated with the anterior segment birefringence of the eyes. Evaluation of normal eyes and an eye with necrotizing scleritis was performed. In the sclera of the normal eyes, a striking polarization change was observed in the cumulative phase retardation images and the boundary of the sclera could be readily detected. In the eye with necrotizing scleritis, phase retardation at the sclera was low in an extensive area; this implied diffuse destruction of the collagen tissue in the sclera had occurred. Polarization-sensitive optical coherence tomography is useful as a contrast engine of the anterior eye segment and for the evaluation of pathological change in the sclera. Copyright 2009, SLACK Incorporated.

Entities:  

Mesh:

Year:  2009        PMID: 19928731     DOI: 10.3928/15428877-20091030-15

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  2 in total

1.  Scleral birefringence as measured by polarization-sensitive optical coherence tomography and ocular biometric parameters of human eyes in vivo.

Authors:  Masahiro Yamanari; Satoko Nagase; Shinichi Fukuda; Kotaro Ishii; Ryosuke Tanaka; Takeshi Yasui; Tetsuro Oshika; Masahiro Miura; Yoshiaki Yasuno
Journal:  Biomed Opt Express       Date:  2014-04-03       Impact factor: 3.732

2.  Foveal localization in non-exudative AMD using scanning laser polarimetry.

Authors:  Dean A VanNasdale; Ann E Elsner; Kimberly D Kohne; Todd D Peabody; Victor E Malinovsky; Bryan P Haggerty; Anke Weber; Christopher A Clark
Journal:  Optom Vis Sci       Date:  2012-05       Impact factor: 1.973

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.